Therapeutic ReviewsMethylene BlueClifton , Jack II1; Leikin, Jerrold B. *Author Information 1Department of Pediatrics, Rush Medical College, Chicago, IL; 2ENH OMEGA, Glenview, IL. Address for correspondence: ENH OMEGA, 2150 Pfingsten Rd, Suite 3000, Glenview, IL 60025, USA. E-mail: JLeikin@enh.org American Journal of Therapeutics: July-August 2003 - Volume 10 - Issue 4 - p 289-291 Buy Abstract Methylene blue finds its major utilization in toxicology in the treatment of methemoglobinemia at a dose of 1 to 2 mg/kg intravenously. By interacting with methemoglobin and the erythrocyte's enzyme systems to reduce back to hemoglobin, methylene blue is a generally safe drug with dose-related hemolytic effects. People with G-6-PD deficiency, along with patients exposed to aniline dyes and dapsone, may present with special risks in the treatment of methemoglobinemia. © 2003 Lippincott Williams & Wilkins, Inc.